Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main target for neutralizing antibodies. These antibodies can be elicited through immunization or passively transferred as therapeutics in the form of convalescent-phase sera or monoclonal antibodies (MAbs).

Guardado en:
Detalles Bibliográficos
Autores principales: Wen Su, Sin Fun Sia, Aaron J. Schmitz, Traci L. Bricker, Tyler N. Starr, Allison J. Greaney, Jackson S. Turner, Bassem M. Mohammed, Zhuoming Liu, Ka Tim Choy, Tamarand L. Darling, Astha Joshi, Ka Man Cheng, Alvina Y. L. Wong, Houda H. Harastani, John M. Nicholls, Sean P. J. Whelan, Jesse D. Bloom, Hui-Ling Yen, Ali H. Ellebedy, Adrianus C. M. Boon
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://doaj.org/article/59017aa8fbfc49cca3569388d8d7b51e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main target for neutralizing antibodies. These antibodies can be elicited through immunization or passively transferred as therapeutics in the form of convalescent-phase sera or monoclonal antibodies (MAbs).